Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bovax 9-valent HPV Vaccine in Chinese Females
NCT03676101Phase 1Completed
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 9-valent HPV recombinant vaccine in human papillomavirus infection, Cervical Cancer (CC), vulvar cancer and 3 more (2 arms), sponsored by Shanghai Bovax Biotechnology Co., Ltd. Primary endpoints: Number of Subjects Reporting Solicited Adverse Events, Number of Subjects Reporting Unsolicited Adverse Events and 1 more. Started Oct 2018; status: completed.
02
Drugs
9-valent HPV recombinant vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)vulvar cancervaginal cancergenital warts
Beyond the preview
Go deeper on NCT03676101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03676101.